Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether INSYS Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as INSYS Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
INSYS Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
INSYS Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through INSYS Therapeutics's regulatory filings and announcements.
INSYS Therapeutics's earnings are expected to grow significantly at over 20% yearly.
INSYS Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
INSYS Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
INSYS Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
INSYS Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
INSYS Therapeutics's long term commitments exceed its cash and other short term assets.
This treemap shows a more detailed breakdown of
INSYS Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
INSYS Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Andrew G. Long, also known as Andy, has been Chief Executive Officer of INSYS Therapeutics, Inc. since April 15, 2019. He served as Chief Financial Officer of INSYS Therapeutics, Inc. since August 07, 2017 until April 15, 2019. Mr. Long is a seasoned finance executive with three decades of experience in the life sciences, bio-pharma and industrial sectors. His extensive skillset includes: corporate and operational finance, strategy, supply chain, information technology, M&A integration and talent acquisition and development. Mr. Long served as Senior Vice President of Patheon Inc from 2015 to 2017 and served as its and Global Business Controller. Prior to his role at Patheon, Mr. Long spent nine years providing management and financial operations expertise as Vice President of Global Finance for multiple divisions at Thermo Fisher Scientific. He previously spent five years directing global financial planning, reporting and analysis activities for the BioScience Division of Cambrex Corporation. Prior to joining Thermo Fisher, he served as vice president of worldwide finance and supply chain management at Cambrex Corporation, responsible for global financial planning, reporting and analysis for a division with 14 manufacturing and distribution sites across 10 countries. Previously, he served in a number of roles of increasing responsibility for companies including Eaton Corporation, Emerson Electric and Abbott Laboratories. Mr. Long holds Bachelor of Science from Indiana University and Master of Business Administration from the Kellogg Graduate School of Business, Northwestern University.
Insufficient data for Andy to compare compensation growth.
Andy's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the INSYS Therapeutics management team is less than 2 years, this suggests a new team.
Chief Executive Officer
Franc Del Fosse
Senior Vice President of Corporate Affairs
Chief Financial Officer
Chief Scientific Officer
Chief Legal Officer & General Counsel
Vice President of Sales
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the INSYS Therapeutics board of directors is less than 3 years, this suggests a new board.
Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.